Dr. Worden is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1500 East Medical Center Dr
B1 Floor Cancer Ctr Recp C
Ann Arbor, MI 48109Phone+1 734-647-8902- Is this information wrong?
Summary
- I am a medical oncologist at the University of Michigan. I specialize in the treatment of head and neck cancers and endocrine malignancies and conduct clinical trials related to these disease entities.
Education & Training
- University of Michigan Health SystemFellowship, Hematology and Medical Oncology, 1997 - 2000
- Detroit Medical Center/Wayne State UniversityResidency, Internal Medicine/Pediatrics, 1993 - 1997
- Indiana University School of MedicineClass of 1993
Certifications & Licensure
- MI State Medical License 1997 - 2025
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors for Cancer Castle Connolly, 2005-2014
- America's Top Doctors Castle Connolly, 2009-2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma Start of enrollment: 2004 Feb 01
- A Study of a New Combination and Schedule of Chemotherapy Drugs for the Treatment of Head and Neck Cancer Start of enrollment: 2002 Nov 01
- Treatment for Patients With Metastatic Thyroid Cancer Start of enrollment: 2005 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- Targeted Therapy and Immunotherapy for Advanced Malignant Conjunctival Tumors: Systematic Review.Serbest Ceylanoglu, K., Guneri Beser, B., Singalavanija, T., Juntipwong, S., Worden, F., Demirci, H.> ;Ophthalmic Plastic and Reconstructive Surgery. 2024 Jan 18
- Use of Cemiplimab, an Immune Checkpoint Inhibitor for Conjunctival Intraepithelial Neoplasia.Ceylanoglu, K., Eisenberg, A., Elner, V., Worden, F., Demirci, H.> ;Cornea. 2024 Apr 1
- Real-world practice patterns and outcomes for RAI-refractory differentiated thyroid cancer.Choe, J., Babajanyan, S., Gianoukakis, A., Bowles, D., Owonikoko, T., Worden, F., Wirth, L., Brose, M.> ;European Thyroid Journal. 2024 Feb 1
- Join now to see all
Journal Articles
- Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid TumorsErin F Cobain, Francis Worden, Scott M Schuetze, Mark M Zalupski, Vaibhav Sahai, Ajjai Alva, Anne F Schott, Moshe Talpaz, JAMA Oncology
- Efficacy of Selpercatinib in RET-Altered Thyroid CancersLori J Wirth, Jochen Lorch, Francis Worden, Marcia Brose, Taofeek K Owonikoko, Mark E Burkard, Todd M Bauer, Viola W Zhu, Nehal Lakhani, Victor Moreno, Manisha H Shah, New England Journal of Medicine
Lectures
- Head and Neck CancerASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019
- Updates on Current Programs and Resources2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Other
- Postoperative radiation therapy in the management of head and neck cancerWorden FP, Eisbruch A, Jolly S
http://www.uptodate.com/contents/postoperative-radiation-therapy-in-the-management-of-head-and-neck-
UpToDate, Wolters Kluwer Health - 2012-02-27 - Treatment of early (stage I and II) head and neck cancer: The oropharynxWorden FP, Eisbruch A, Bradford CR
http://www.uptodate.com/contents/treatment-of-early-stage-i-and-ii-head-and-neck-cancer-the-orophary
UpToDate, Wolters Kluwer Health - 2012-10-31 - Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The oropharynxWorden FP, Eisbruch A, Bradford CR
http://www.uptodate.com/contents/treatment-of-locoregionally-advanced-stage-iii-and-iv-head-and-neck
UpToDate, Wolters Kluwer Health - 2012-06-05
Authored Content
- Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
- Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
- Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
Press Mentions
- Axitinib Improves Survival for Patients with Incurable Head and Neck CancerOctober 20th, 2020
- Racial, Socioeconomic Disparities Found Among Patients with HPV-Positive Oropharyngeal CancerFebruary 6th, 2020
- New Treatments, New Outcomes for Refractory Thyroid CancerJuly 10th, 2019
- Join now to see all
Committees
- Member, Committee on Appropriateness Criteria, Expert Panel on Radiation Oncology - Head & Neck Cancer, American College of Radiology 2015 - Present
Professional Memberships
- Member
Hospital Affiliations
- University of Michigan Medical CenterAnn Arbor, Michigan
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: